FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104477572> ?p ?o ?g. }

• W2104477572 endingPage "2873" @default.
• W2104477572 startingPage "2863" @default.
• W2104477572 abstract "Purpose To evaluate the association of germ-line polymorphisms of genes that may impact treatment outcome of platinum and fluorouracil combination chemotherapy in advanced gastric cancer (AGC). Patients and Methods Blood samples of 156 patients enrolled onto a phase III study comparing fluorouracil, leucovorin, and oxaliplatin with fluorouracil, leucovorin, and cisplatin were collected. Polymorphisms within genes of TS, MTHFR, MTR, OPRT, XPD, ERCC1, XRCC1, XPA, GSTP1, GSTT1, and GSTM1 were genotyped using polymerase chain reaction–based techniques. Results Median overall survival (OS) was 11.8 months (95% CI, 9.75 to 13.79 months) and median progression-free survival (PFS) was 5.8 months (95% CI, 4.99 to 6.61 months). The TS-3R/+6 haplotype (P = .004), the GSTT1 deletion polymorphism (P = .015), and genotypes of OPRT-Gly213Ala (P = .003) and XRCC1-Arg399Gln (P = .023) could be identified as independent predictors of OS. For PFS analyses, the TS-3R/+6 haplotye (P = .003) and MTR-A2756G (P = .01) were identified as independent positive predictors. The association between the GSTT1 deletion polymorphism and PFS showed only borderline significance (P = .053). Treatment related hematotoxicity in terms of grade 3/4 leukopenia was lowest among TS-3R/+6 haplotype carriers (P = .037). Grade 3/4 neutropenia was directly associated with the MTR-2756G/G genotype (P = .011), GSTP1-105Ile/Ile genotype (P = .02), and with the ERCC1-118T/8092C-haplotype (P = .042). In addition, significant associations between GSTP1-105Ile/Ile genotype and neurotoxicity and between the XPD-Asn312/751Gln haplotype and nephrotoxicity could be identified (P = .028 and P = .005, respectively). Conclusion These findings underline the hypothesis that germ-line polymorphisms may play an important role in individualizing chemotherapy in AGC and deserve further prospective evaluation in AGC patients." @default.
• W2104477572 created "2016-06-24" @default.
• W2104477572 creator A5007449495 @default.
• W2104477572 creator A5012380788 @default.
• W2104477572 creator A5017002895 @default.
• W2104477572 creator A5032057646 @default.
• W2104477572 creator A5040708686 @default.
• W2104477572 creator A5064487920 @default.
• W2104477572 creator A5065638372 @default.
• W2104477572 creator A5072163653 @default.
• W2104477572 creator A5078383767 @default.
• W2104477572 creator A5080582735 @default.
• W2104477572 date "2009-06-10" @default.
• W2104477572 modified "2023-09-27" @default.
• W2104477572 title "Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie" @default.
• W2104477572 cites W1504784308 @default.
• W2104477572 cites W1850914599 @default.
• W2104477572 cites W1972248724 @default.
• W2104477572 cites W1977022507 @default.
• W2104477572 cites W1977439202 @default.
• W2104477572 cites W1981748018 @default.
• W2104477572 cites W1983585864 @default.
• W2104477572 cites W1988675954 @default.
• W2104477572 cites W2001337137 @default.
• W2104477572 cites W2002291152 @default.
• W2104477572 cites W2010523495 @default.
• W2104477572 cites W2022844202 @default.
• W2104477572 cites W2024042560 @default.
• W2104477572 cites W2030108537 @default.
• W2104477572 cites W2033326364 @default.
• W2104477572 cites W2042143199 @default.
• W2104477572 cites W2043445391 @default.
• W2104477572 cites W2059700063 @default.
• W2104477572 cites W2065829703 @default.
• W2104477572 cites W2067388814 @default.
• W2104477572 cites W2072445683 @default.
• W2104477572 cites W2092470860 @default.
• W2104477572 cites W2096865519 @default.
• W2104477572 cites W2101804080 @default.
• W2104477572 cites W2104637985 @default.
• W2104477572 cites W2108661938 @default.
• W2104477572 cites W2122332780 @default.
• W2104477572 cites W2124714901 @default.
• W2104477572 cites W2125173168 @default.
• W2104477572 cites W2127961360 @default.
• W2104477572 cites W2128775037 @default.
• W2104477572 cites W2131463911 @default.
• W2104477572 cites W2139687160 @default.
• W2104477572 cites W2146434000 @default.
• W2104477572 cites W2150847936 @default.
• W2104477572 cites W2153591132 @default.
• W2104477572 cites W2156214772 @default.
• W2104477572 cites W2158118791 @default.
• W2104477572 cites W2159801780 @default.
• W2104477572 cites W2162507937 @default.
• W2104477572 cites W2162998038 @default.
• W2104477572 cites W2166509493 @default.
• W2104477572 cites W2168284699 @default.
• W2104477572 cites W2168715864 @default.
• W2104477572 cites W2171062435 @default.
• W2104477572 cites W2200882253 @default.
• W2104477572 cites W2287320568 @default.
• W2104477572 cites W2295706507 @default.
• W2104477572 cites W4236794905 @default.
• W2104477572 doi "https://doi.org/10.1200/jco.2008.19.1718" @default.
• W2104477572 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19332728" @default.
• W2104477572 hasPublicationYear "2009" @default.
• W2104477572 type Work @default.
• W2104477572 sameAs 2104477572 @default.
• W2104477572 citedByCount "113" @default.
• W2104477572 countsByYear W21044775722012 @default.
• W2104477572 countsByYear W21044775722013 @default.
• W2104477572 countsByYear W21044775722014 @default.
• W2104477572 countsByYear W21044775722015 @default.
• W2104477572 countsByYear W21044775722016 @default.
• W2104477572 countsByYear W21044775722017 @default.
• W2104477572 countsByYear W21044775722018 @default.
• W2104477572 countsByYear W21044775722019 @default.
• W2104477572 countsByYear W21044775722020 @default.
• W2104477572 countsByYear W21044775722021 @default.
• W2104477572 countsByYear W21044775722022 @default.
• W2104477572 countsByYear W21044775722023 @default.
• W2104477572 crossrefType "journal-article" @default.
• W2104477572 hasAuthorship W2104477572A5007449495 @default.
• W2104477572 hasAuthorship W2104477572A5012380788 @default.
• W2104477572 hasAuthorship W2104477572A5017002895 @default.
• W2104477572 hasAuthorship W2104477572A5032057646 @default.
• W2104477572 hasAuthorship W2104477572A5040708686 @default.
• W2104477572 hasAuthorship W2104477572A5064487920 @default.
• W2104477572 hasAuthorship W2104477572A5065638372 @default.
• W2104477572 hasAuthorship W2104477572A5072163653 @default.
• W2104477572 hasAuthorship W2104477572A5078383767 @default.
• W2104477572 hasAuthorship W2104477572A5080582735 @default.
• W2104477572 hasBestOaLocation W21044775721 @default.
• W2104477572 hasConcept C104317684 @default.
• W2104477572 hasConcept C104451858 @default.
• W2104477572 hasConcept C121608353 @default.
• W2104477572 hasConcept C123321153 @default.

• next